[Oncologic and functional results of 57 malignant melanoma of the uvea treated by curietherapy].
Fifty-seven uveal malignant melanomas (T2: 36.8%; T3: 49.1%) were treated between 1983 and 1989 with Cobalt 60 or/and Ruthenium 106 Rhodium 106 plaques. The mean follow-up was 32 months (from 6 to 69 months). A diminution of tumor size was observed in 88% of the cases, either rapid and marked (57%), or slower and more moderate (31%). A multivariate study showed the radiation dose administered to the tumor edge to be the most significant parameter associated with the tumor control. Seven patients developed metastases, and the probability of survival at 60 months was 83.3%. This probability was identical to that of 59 comparable patients treated, some years before, by enucleation. The most frequent complications were radiation retinopathy (28.1%) and retinal detachment (15.8%). The treated eye was retained in 86% of cases. In 57% of treated eyes, vision remained better or equal to 0.1. The predictive parameters of vision impairment after treatment seemed to be tumor size, tumor site near the macula and the optic nerve, and the radiation dose to the tumor base. The use of Ruthenium 106 Rhodium 106 appeared to be advantageous in controlling the disease as well as in reducing the incidence of complications.
Bacin
F
F
Service d'Ophtalmologie, Hôpital G. Montpied, Clermont-Ferrand, France.
Albuisson
E
E
Rozan
R
R
Donnarieix
D
D
Verrelle
P
P
Dalens
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors; D014604:Uveal Neoplasms / Q000532:radiotherapy*; D014792:Visual Acuity
Résultats carcinologiques et fonctionnels de 57 mélanomes malins de l'uvée traités par curiethérapie.